Wednesday, July 20, 2016 10:31:00 AM
Of course, it may not amount to the nearly 20% of the current O/S after the 1:30,000 R/S that's planned. Unless, there's an anti dilution clause attached to them. But I doubt that since 8687544 Canada Inc is to receive 30,000,000 shares after the R/S for the supposed rights title and interest in the Injex needle.
Of course, it may all be moot if 8687544 Canada doesn't actually have the rights to the Injex needle as they claim.
Hopefully, that'll be cleared up shortly.
You can lead a horse to water. But you can't make him get down on one knee and do an Al Jolson impression!
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM